美泊利珠单抗与贝那利珠单抗在重度哮喘中的疗效比较
两组基线特征相似,但美泊利珠单抗组基线ACQ更高、FEV1%更低。治疗6个月和12个月后,贝那利珠单抗在减少急性发作、改善FEV1和降低血嗜酸性粒细胞方面显著优于美泊利珠单抗。
要点
- 贝那利珠单抗在减少需口服激素的急性发作方面优于美泊利珠单抗。
- 贝那利珠单抗对FEV1的改善幅度大于美泊利珠单抗。
- 贝那利珠单抗降低血嗜酸性粒细胞计数的作用更强。
核心结论
- 在重度嗜酸性哮喘患者中,美泊利珠单抗和贝那利珠单抗均改善疾病参数,但贝那利珠单抗在减少急性发作、改善FEV1和降低血嗜酸性粒细胞方面显著更有效。
主要发现
- 治疗12个月时,贝那利珠单抗减少急性发作频率的幅度比美泊利珠单抗大64%(p=0.01)。
临床怎么用
- 对于重度嗜酸性哮喘患者,贝那利珠单抗在减少急性发作和改善肺功能方面可能优于美泊利珠单抗,选择生物制剂时可考虑此差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: This study compared the clinical outcomes of severe asthmatics treated with mepolizumab and benralizumab in a tertiary care severe asthma service setting. METHODS: Patient data at baseline, six and 12 months were collected prospectively at two large tertiary hospital severe asthma clinics following treatment initiation. Two hundred and four patients received treatment with mepolizumab (117) or benralizumab (87). Baseline characteristics between groups were similar in regard to age, gender, body mass index, steroid dose and blood eosinophil count. However, the mepolizumab cohort had a higher Asthma Control Questionnaire Score (ACQ) at baseline (4.0 ± 1.1 vs. 3.6 ± 0.9, p = 0.018), accompanied by more frequent reliever medication usage and lower prebronchodilator FEV1 % (56.0 ± 20.1 vs. 63.8 ± 18.9, p = 0.008). RESULTS: After 6 months treatment, both treatments induced significant improvements in (i) ACQ of 2.3 ± 0.1 (p < 0.001), (ii) oral steroid requiring exacerbations (incident rate ratio 0.26 (0.18-0.37), p < 0.001) and (iii) FEV1 . However, the improvement in FEV1 was 0.18 (0.05-0.30) litres greater with benralizumab than with mepolizumab (p = 0.002) even when adjusting statistically for baseline differences between groups. These differences were even more pronounced at 12 months post-treatment initiation, when the improvement in exacerbation frequency with benralizumab was 64% greater than with mepolizumab (p = 0.01). Whilst both treatments significantly reduced the blood eosinophil count at 6 and 12 months, this reduction was substantially greater with benralizumab than mepolizumab (-260 cells/μL [-400 to -110, p = 0.001]). CONCLUSION: In this large group of severe eosinophilic asthmatics, mepolizumab and benralizumab both improved disease parameters. However, benralizumab treatment appeared significantly more effective than mepolizumab in reducing exacerbations, improving FEV1 and depleting blood eosinophils.
引用
- Langton, Politis, Collyer, et al. Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics. Respirology. 2023. PMID: 37638723. doi:10.1111/resp.14578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。